NEW YORK--(BUSINESS WIRE)--The Rosen Law Firm, P.A. announces that it is investigating the Board of Directors of Durata Therapeutics, Inc. (NASDAQ:DRTX) for possible breaches of fiduciary duty and other violations of law by failing to adequately shop Durata to maximize shareholder value before agreeing to be acquired by Actavis plc (NYSE:ACT).
If you would like to join the action, go to http://rosenlegal.com/cases-387.html or contact Phillip Kim or Kevin Chan, toll-free at 866-767-3653, or via e-mail at firstname.lastname@example.org or email@example.com. There is no cost or obligation to you.
Under the terms of the proposed transaction, shareholders will receive $23.00 in cash and the right to receive an additional payment of up to $5.00 per share, if certain goals are reached, for each share of Durata they own. The proposed transaction is valued at approximately $675 million. The investigation relates to whether the proposal for $23.00 in cash and the right to receive an additional payment of up to $5.00 per share is fair to public shareholders and whether Durata’s Board breached its fiduciary duties in connection with the proposed sale.
If you currently own shares of Durata and wish to obtain additional information, please visit the website at http://rosenlegal.com/cases-387.html. You may also contact Phillip Kim or Kevin Chan of The Rosen Law Firm toll free at 866-767-3653 or via e-mail at firstname.lastname@example.org or email@example.com.
The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Attorney Advertising. Prior results do not guarantee a similar outcome.